These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3217382)

  • 1. [Antibodies to the plasma membranes of thyrocytes in patients with diffuse toxic goiter during treatment with mercazole].
    Saarma VA; Podar TU
    Probl Endokrinol (Mosk); 1988; 34(5):17-9. PubMed ID: 3217382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dynamics of thyrostimulating immunoglobulin levels during treatment of diffuse toxic goiter].
    Sviridenko NIu; Mkrtukova NA; Kraĭnova SI; Nefedov SB; Kandror VI
    Probl Endokrinol (Mosk); 1991; 37(1):15-7. PubMed ID: 1674150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of mercasolyl on immunologic indicators in patients with diffuse toxic goiter].
    Epishin AV; Solomko LD; Epishina NA; Kuz'mich IuP
    Vrach Delo; 1989 Feb; (2):11-4. PubMed ID: 2711649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The presence of antithyroid antibodies in the blood serum of patients with diffuse toxic goiter before and during treatment].
    Khalling TA; Iarvekiul'g LV
    Probl Endokrinol (Mosk); 1990; 36(5):18-20. PubMed ID: 2080137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in the immune status indices of patients with diffuse toxic goiter in different stages of the disease].
    Livshits AKh; Oleĭnik EK
    Probl Endokrinol (Mosk); 1985; 31(6):6-10. PubMed ID: 3841395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of merkazolyl on the level of thyrostimulating immunoglobulins of the blood in patients with diffuse toxic goiter].
    Oleĭnik VA; Khalangot ND
    Probl Endokrinol (Mosk); 1989; 35(1):32-5. PubMed ID: 2717572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioisotope methods of control of the effectiveness of treatment of diffuse toxic goiter with mercazolyl].
    Egorenkov AN
    Med Radiol (Mosk); 1976; 21(9):47-53. PubMed ID: 1036752
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter].
    Iangolenko VV
    Ter Arkh; 1991; 63(10):60-3. PubMed ID: 1725225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of different doses of reserpine on thyroid function and on the effect of mercazolyl in the treatment of diffuse toxic goiter].
    Komarovskaia RP
    Sov Med; 1970 Nov; 33(11):114-7. PubMed ID: 4107499
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interactions between serum antibodies of patients with autoimmune thyropathies and isolated cells of diffuse toxic euthyroid nodular goiter].
    Kraĭnova SI; Kandror VI
    Probl Endokrinol (Mosk); 1993; 39(6):46-50. PubMed ID: 8290513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamics of interleukin 2 production in patients with diffuse toxic goiter under the influence of treatment].
    Shatsova EN; Malaitsev VV; Bogdanova IM
    Probl Endokrinol (Mosk); 1988; 34(6):24-6. PubMed ID: 2976937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of thyroid-stimulating antibodies in goitrous disease assessed by cytochemical section bioassay.
    Smyth PP; Neylan D; O'Donovan DK
    J Clin Endocrinol Metab; 1982 Feb; 54(2):357-61. PubMed ID: 6119323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
    Bossowski A; Czarnocka B; Bardadin K; Urban M; Niedziela M; Dadan J
    Horm Res; 2008; 70(3):155-64. PubMed ID: 18663316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of Yersinia infection in the pathogenesis of diffuse toxic goiter].
    Panova TN; Pogorelova NP; Rashevskaia EV
    Ter Arkh; 1990; 62(12):93-5. PubMed ID: 2084934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [T-cell immunity and immunomodulators in the comprehensive treatment of diffuse toxic goiter].
    Petunina NA; Balabolkin MI; Arion VIa
    Ross Med Zh; 1992; (5-12):19-24. PubMed ID: 1286263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of diffuse euthyroid goiter with indomethacin].
    Tsitsiashvili BSh; Mirkhodzhaeva AKh; Kalistratova TN; Gaĭdina GA; Maĭorov AIu
    Probl Endokrinol (Mosk); 1990; 36(2):26-8. PubMed ID: 2362924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of thyroid gland injury during goiter (morphofunctional parallels) in various regions of Georgia.
    Gogiashvili L; Giorgadze E; Nikobadze E; Chachibaya V; Tsagareli Z
    Georgian Med News; 2007 May; (146):77-81. PubMed ID: 17595470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodinating activity of thyroid tissue in toxic diffuse goiter.
    Nagataki S; Uchimura H; Ikeda H; Kuzuya N; Masuyama Y
    J Clin Invest; 1977 Apr; 59(4):723-9. PubMed ID: 576614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.